Method for treating amyloidosis
Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.
Claims
1. A method for inhibiting amyloid deposition in a subject comprising administering to the subject an effective amount of a therapeutic compound, the therapeutic compound comprising at least one sulfonate group covalently attached to a carrier molecule, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the therapeutic compound is administered orally.
3. The method of claim 1, wherein the carrier molecule is selected from the group consisting of a polymer, a peptide, a peptidomimetic, an aliphatic group, an alicyclic group, a heterocyclic group, and combinations thereof.
4. The method of claim 3, wherein the carrier molecule is an aliphatic group.
5. The method of claim 4, wherein the therapeutic compound is selected from the group consisting of ethanesulfonic acid, 1,2-ethanedisulfonic acid, 1-propanesulfonic acid, 1,3-propanedisulfonic acid, 1,4-butanedisulfonic acid, 1,5-pentanedisulfonic acid, 2-aminoethanesulfonic acid, 4-hydroxybutane-1-sulfonic acid, and pharmaceutically acceptable salts thereof.
6. The method of claim 1, wherein the therapeutic compound is selected from the group consisting of 1-butanesulfonic acid, 1-decanesulfonic acid, 2-propanesulfonic acid, 3-pentanesulfonic acid, 4-heptanesulfonic acid, and pharmaceutically acceptable salts thereof.
7. The method of claim 1, wherein the therapeutic compound is 1,7-dihydroxy-4-heptanesulfonic acid, or a pharmaceutically acceptable salt thereof.
8. A method for inhibiting amyloid deposition in a subject comprising administering to the subject an effective amount of a therapeutic compound, the therapeutic compound comprising at least one sulfate group covalently attached to a carrier molecule; or a pharmaceutically acceptable salt thereof.
9. The method of claim 8, wherein the therapeutic compound is administered orally.
10. The method of claim 8, wherein the carrier molecule is selected from the group consisting of a polymer, a peptide, a peptidomimetic, an aliphatic group, an alicyclic group, a heterocyclic group, and combinations thereof.
11. The method of claim 10, wherein the carrier molecule is an aliphatic group.
12. The method of claim 8, wherein the therapeutic compound is selected from the group consisting of 2-hydroxymethyl-1,3-propanediol disulfate, 2-hydroxymethyl-2-methyl-1,3-propanediol disulfate, 1,3-cyclohexanediol disulfate, and pharmaceutically acceptable salts thereof.
13. The method of claim 8, wherein the therapeutic compound is 2,3,4,3',4'-sucrose pentasulfate, or a pharmaceutically acceptable salt thereof.
14. The method of claim 8, wherein the therapeutic compound is selected from the group consisting of 2-hydroxyethylsulfamic acid disulfate, 3-hydroxypropylsulfamic acid sulfate, and pharmaceutically acceptable salts thereof.
15. The method of claim 8, wherein the therapeutic compound is selected from the group consisting of 1,3,5,7-heptanetetraol tetrasulfate and 1,3,5,7,9-nonanepentaol pentasulfate, and pharmaceutically acceptable salts thereof.
16. The method of claim 1, wherein the carrier molecule comprises a targeting moiety.
17. The method of claim 8, wherein the carrier molecule comprises a targeting moiety.
18. A method for inhibiting amyloid deposition in a subject comprising administering to the subject an effective amount of a therapeutic compound, the therapeutic compound comprising at least one tetrazole group covalently attached to a carrier molecule, or a pharmaceutically acceptable salt thereof.
19. The method of claim 18, wherein the therapeutic compound is selected from the group consisting of 3-(1H-tetrazol-5-yl)-9H-thioxanthen-9-one 10,10-dioxide, 5,5-dithiobis(1-phenyltetrazole), 1H-tetrazole, 5-phenyl-1H-tetrazole, and 5-(2-aminoethanoic acid)-1H-tetrazole, and pharmaceutically acceptable salts thereof.
20. The method of claim 18, wherein the carrier molecule comprises a targeting moiety.
21. The method of claim 1, wherein the carrier molecule is selected from the group consisting of an aromatic group, a carbohydrate, and combinations thereof.
22. The method of claim 8, wherein the carrier molecule is selected from the group consisting of an aromatic group, a carbohydrate, and combinations thereof.
23. A method for inhibiting amyloid deposition in a subject comprising administering to the subject an effective amount of a therapeutic compound, or a pharmaceutically acceptable salt thereof, such that amyloid deposition is inhibited, the therapeutic compound having the formula:
- wherein the carrier molecule comprises a targeting moiety.
24. The method of claim 23, wherein the therapeutic compound is administered orally.
25. The method of claim 23 further comprising administering the therapeutic compound in a pharmaceutically acceptable vehicle.
26. The method of claim 23, wherein the carrier molecule is selected from the group consisting of a polymer, a peptide, a peptidomimetic, an aliphatic group, an alicyclic group, a heterocyclic group, and combinations thereof.
27. The method of claim 23, wherein the carrier molecule is selected from the group consisting of an aromatic group, a carbohydrate, and combinations thereof.
28. The method of claim 23, wherein n is an integer between 1 and 10.
29. The method of claim 23, wherein the anionic group is selected from the group consisting of a sulfonate group, a sulfate group, a carboxylate group, a phosphate group, a phosphonate group, ##STR3##
30. The method of claim 23, wherein the targeting moiety targets the therapeutic compound to the brain.
31. The method of claim 23, wherein the targeting moiety comprises an amino acid mimetic.
32. The method of claim 23, wherein the targeting moiety comprises a thyroxine mimetic.
33. The method of claim 23, wherein the targeting moiety allows transport of the therapeutic compound into cells by receptor-mediated endocytosis.
34. A method for inhibiting amyloid deposition in a subject comprising administering to the subject an effective amount of a prodrug, or a pharmaceutically acceptable salt thereof, wherein the prodrug is converted in vivo to a therapeutic compound, such that amyloid deposition is inhibited, the therapeutic compound having the formula:
35. The method of claim 34, wherein the prodrug is administered orally.
36. The method of claim 34, further comprising administering the prodrug in a pharmaceutically acceptable vehicle.
37. The method of claim 34, wherein the carrier molecule is selected from the group consisting of a polymer, a peptide, a peptidomimetic, a carbohydrate, an aliphatic group, an alicyclic group, a heterocyclic group, and combinations thereof.
38. The method of claim 34, wherein the anionic group is selected from the group consisting of a sulfonate group, a sulfate group, a carboxylate group, a phosphate group, a phosphonate group, ##STR4##
39. The method of claim 34, wherein the prodrug is an ester of a sulfate or a sulfonate.
40. The method of claim 39, wherein the prodrug is a cyclic ester.
41. The method of claim 39, wherein the prodrug is cleaved in vivo reductively or hydrolytically when the prodrug is administered to the subject.
42. The method of claim 34, wherein the carrier molecule comprises a targeting moiety.
43. The method of claim 42, wherein the targeting moiety targets the therapeutic compound to the brain.
44. The method of claim 42, wherein the targeting moiety comprises an amino acid mimetic.
45. The method of claim 42, wherein the targeting moiety comprises a thyroxine mimetic.
46. The method of claim 42, wherein the targeting moiety allows transport of the therapeutic compound into cells by receptor-mediated endocytosis.
47. A pharmaceutical composition for treating amyloidosis comprising a therapeutic compound, or a pharmaceutically acceptable salt thereof, in an amount sufficient to inhibit amyloid deposition in a subject, and a pharmaceutically acceptable vehicle, the therapeutic compound having the formula:
- wherein the carrier molecule comprises a targeting moiety.
48. The pharmaceutical composition of claim 47, wherein the carrier molecule is selected from the group consisting of a polymer, a peptide, a peptidomimetic, an aliphatic group, an alicyclic group, a heterocyclic group, and combinations thereof.
49. The pharmaceutical composition of claim 47, wherein the carrier molecule is selected from the group consisting of an aromatic group, a carbohydrate, and combinations thereof.
50. The pharmaceutical composition of claim 47, wherein n is an integer between 1 and 10.
51. The pharmaceutical composition of claim 47, wherein the anionic group is selected from the group consisting of a sulfonate group, a sulfate group, a carboxylate group, a phosphate group, a phosphonate group, ##STR5##
52. The pharmaceutical composition of claim 47, wherein the targeting moiety targets the therapeutic compound to the brain.
53. The pharmaceutical composition of claim 47, wherein the targeting moiety comprises an amino acid mimetic.
54. The pharmaceutical composition of claim 47, wherein the targeting moiety comprises a thyroxine mimetic.
55. The pharmaceutical composition of claim 47, wherein the targeting moiety allows transport of the therapeutic compound into cells by receptor-mediated endocytosis.
56. A pharmaceutical composition for inhibiting amyloid deposition in a subject comprising a prodrug, or a pharmaceutically acceptable salt thereof, in an amount sufficient to inhibit amyloid deposition in a subject, wherein the prodrug is converted in vivo to a therapeutic compound, the therapeutic compound having the formula:
- and a pharmaceutically acceptable vehicle.
57. The pharmaceutical composition of claim 56, wherein the carrier molecule is selected from the group consisting of a polymer, a peptide, a peptidomimetic, a carbohydrate, an aliphatic group, an alicyclic group, a heterocyclic group, and combinations thereof.
58. The pharmaceutical composition of claim 56, wherein the anionic group is selected from the group consisting of a sulfonate group, a sulfate group, a carboxylate group, a phosphate group, a phosphonate group, ##STR6##
59. The pharmaceutical composition of claim 56, wherein the prodrug is an ester of a sulfate or a sulfonate.
60. The pharmaceutical composition of claim 59, wherein the prodrug is a cyclic ester.
61. The pharmaceutical composition of claim 56, wherein the prodrug is cleaved in vivo reductively or hydrolytically when the prodrug is administered to the subject.
62. The pharmaceutical composition of claim 56, wherein the carrier molecule comprises a targeting moiety.
63. The pharmaceutical composition of claim 62, wherein the targeting moiety targets the therapeutic compound to the brain.
64. The pharmaceutical composition of claim 62, wherein the targeting moiety comprises an amino acid mimetic.
65. The pharmaceutical composition of claim 62, wherein the targeting moiety comprises a thyroxine mimetic.
66. The pharmaceutical composition of claim 62, wherein the targeting moiety allows transport of the therapeutic compound into cells by receptor-mediated endocytosis.
| 5242932 | September 7, 1993 | Gandy et al. |
| 5276059 | January 4, 1994 | Caughey et al. |
| 5385915 | January 31, 1995 | Buxbaum et al. |
| 0 464 759 A2 | January 1992 | EPX |
- Caughey, B. and Raymond, G. J., (1993), "Sulfated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells", Journal of Virology, vol. 67, No. 2, pp. 643-650. Travis, (1993), "New Piece in Alzheimer's Puzzle", Science, vol. 261, pp. 828-829. Kisilevsky et al., (1992), "A Critical Analysis of Postulated Pathogenetic Mechanisms in Amyloidogenesis", Critical Reviews in Clinical Laboratory Sciences, vol. 29, No. 1, pp. 59-82. Young et al., (1992), "Localization of the Basement Membrane Heparan Sulfate Proteoglycan in Islet Amyloid Deposits in Type II Diabetes Mellitus", Arch. Pathol. Lab. Med., vol. 116, pp. 951-954. Dow et al., (1992), "Effects of 4-deoxy-L-threo-pentose, a novel carbohydrate, on neural cell proteoglycan synthesis and function", Biochimica et Biophysica Acta, vol. 1156, pp. 7-14. Narindrasorasak et al., (1992), "Characterization of High Affinity Binding between Laminin and Alzheimer's Disease Amyloid Precursor Proteins", Laboratory Investigation, vol. 67, No. 5, pp. 643-652. Small et al., (1992), "Association and Release of the Amyloid Protein Precursor of Alzheimer's Disease from Chick Brain Extracellular Matrix", The Journal of Neuroscience, vol. 12, No. 11, pp. 4143-4150. Fraser et al., (1992), "Effects of Sulfate Ions on ALzheimer-beta/A4 Peptide Assemblies--Implications for Amyloid Fibril-Proteoglycan Interactions", J. Neurochem., vol. 59, pp. 1531-1540. Narindrasorasak et al., (1991), "High Affinity Intereactions between the Alzheimer's .beta.-Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", The Journal of Biological Chemistry, vol. 266, No. 20, pp. 12878-12883. Lyon et al., (1991), "Co-deposition of Basement Membrane Components during the Induction of murine Splenic AA Amyloid", Laboratory Investigation, vol. 64, No. 6, pp. 785-790. Snow et al., (1991), "A Temporal and Ultrastructural Relationship Between Heparan Sulfate Proteoglycans and AA Amyloid in Experimental Amyloidosis", The Journal of Histochemistry and Cytochemistry, vol. 39, No. 10, pp. 1321-1330. Wong et al., (1990), "Influence of Sulphate ions on the Structure of AA Amyloid Fibrils", Scand. J. Immunol., vol. 32, pp. 225-232. Kisilevsky, (1990), "Heparan Sulfate Proteoglycans in Amyloidogenesis: An Epiphenomenon, A Unique Factor, or the Tip of a More Fundamental Process?", Laboratory Investigation, vol. 63, No. 5, pp. 589-591. Young et al., (1989), "The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis", Acta Neuropathol., vol., 78, pp. 202-209. Brissette et al., (1989), "Differential Induction of the Serum Amyloid A Gene Family in Response to an Inflammatory Agent and to Amyloid-enhancing Factor", The Journal of Biological Chemistry, vol. 264, No. 32, pp. 19327-19332. Snow et al., (1989), "Sulfated glycosaminoglycans in amyloid plaques of prion diseases", Acta Neuropathol., vol. 77, pp. 337-342. Kisilevsky, (1989), "Theme and Variations on a String of Amyloid", Neurobiology of Aging, vol. 10, pp. 499-500. Kisilevsky, R. and Snow, A., (1988), "The Potential Significance of Sulphated Glycosaminoglycans as a Common Constituent of all Amyloids: or Perhaps Amyloid is not a Misnomer", Medical Hypotheses, vol. 26, pp. 231-236. McCubbin et al., (1988), "Circular-dichroism studies on two murine serum amyloid A proteins", Biochem. J., vol. 256, pp. 775-783. Tape et al., (1988), "Direct Evidence for Circulating apoSAA as the Precursor of Tissue AA Amyloid Deposits", Scand. J. Immunol., vol. 28, pp. 317-324. Kisilevsky, (1987), "From arthritis to Alzheimer's disease: current concepts on the pathogenesis of amyloidosis", Can. J. Physiol. Pharmacol., vol. 65, pp. 1805-1815. Snow et al., (1987), "Sulfated Glycosaminoglycans in Alzheimer's Disease", Human Pathology, vol. 18, No. 5, pp. 506-510. Snow et al., (1987), "Characterization of Tissue and Plasma Glycosaminoglycans during Experimental AA Amyloidosis and Acute Inflammation", Laboratory Investigation, vol. 56, No. 6, pp. 665-675. Snow et al., (1987), "A Close Ultrastructural Relationship between Sulfated Proteoglycans and AA Amyloid Fibrils", Laboratory Investigation, vol. 57, No. 6, pp. 687-697. Snow et al., (1987), "Sulfated Glycosaminoglycans: A Common Constituent of All Amyloids?", Laboratory Investigation, vol. 56, No. 1, pp. 120-123. Snow, A. D. and Kisilevsky, R., (1985), "Temporal Relationship between Glycosaminoglycan Accumulation and Amyloid Deposition during Experimental Amyloidosis", Laboratory Investigation, vol. 53, No. 1, pp. 37-43. Ehlers et al., (1984), "Dextran Sulphate 500 Delays and Prevents Mouse Scrapie by Impairment of Agent Replication in Spleen", J. Gen. Virol., vol. 65, pp. 1325-1330. Puchtler et al., (1983), "Application of Thiazole Dyes to Amyloid Under Conditions of Direct cotton Dyeing: Correlation of Histochemical and Chemical Data", Histochemistry, vol. 77, pp. 431-445. Axelrad et al., (1982), "Further Characterization of Amyloid Enhancing Factor", Laboratory Investigation, vol. 47, pp. 139-146. Leveugle, B. et al., (1994), "Binding of heparan sulfate glycosaminoglycan to .beta.-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds", NeuroReport, vol. 5, pp. 1389-1392. Caughey, B. et al., (1994), "Binding of the Protease-Sensitive Form of Prion Protein PrP to Sulfated Glysocaminoglycan and Congo Red", Journal of Virology, vol. 68, pp. 2135-2141. Caughey, B., (1993), "Scrapie-Associated PrP Accumulation and Its Prevention: Insights from Cell Culture", Brit. Med. Bull., vol. 49, pp. 860-872. Caughey, B., (1994), "Protease-resistant PrP accumulation and scrapie agent replication: a role for sulphated glycosaminoglycans?", Biochem. Soc. Trans., vol. 22, pp. 163-167. Caughey, B., (1994), "Scrapie-associated PrP accumulation and agent replication: effects of sulphated glycosaminoglycan analogues", Phil. Trans. R. Soc. Lond. B, vol. 343, pp. 399-404. Kagan, D.Z. and Rozinova, V.N. (1974) "Inhibition of amyloidosis with Congo Red in experimental amyloidosis", Problemy Tuberkuleza, vol. 40, pp. 72-74. (with English translation). Kisilevsky, R. et al., (1995), "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease", Nature Med. vol. 1, pp. 143-148.
Type: Grant
Filed: Oct 13, 1995
Date of Patent: Nov 24, 1998
Assignee: Queen's University at Kingston (Kingston)
Inventors: Robert Kisilevsky (Kingston), Walter Szarek (Kingston), Donald Weaver (Kingston)
Primary Examiner: Carlos Azpuru
Law Firm: Lahive & Cockfield, LLP
Application Number: 8/542,997
International Classification: A61K 3174; A61K 31785; A61K 31795; A61F 202;
